Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP1189 add-on therapy in idiopathic membranous nephropathy with severe proteinuria
2020-000971-18Phase 2Active
- Sponsor
- SynAct Pharma AB
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in idiopathic membranous glomerulonephritis (IMG) comparing AP1189 add-on with Placebo add-on (2 arms). Primary endpoint: Safety over 12 weeks. Started Apr 2020; status: active.
02
Drugs
resomelagon
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on 2020-000971-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000971-18.